Literature DB >> 31879326

Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies.

Thomas Pincez1, Julie Bruneau1, Laureline Berteloot2, Eve Piekarski3, Caroline Thomas4, Ambroise Marçais5, Amélie Trinquand6, Martin Castelle1, Nicolas Garcelon7, Dominique Plantaz8, Morgane Cheminant1, Despina Moshous1, Thierry Jo Molina1, Olivier Hermine1, Elizabeth Macintyre1, Alain Fischer1, Stéphane Blanche1, Felipe Suarez1, Bénédicte Neven9.   

Abstract

Keywords:  Cell Therapy and Immunotherapy; Hematopoietic Stem Cell; Immunodeficiencies; Lymphoproliferative Disorders

Year:  2019        PMID： 31879326      PMCID： PMC7556515          DOI： 10.3324/haematol.2019.230276

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.

Authors:  Michael T Meister; Sandra Voss; Dirk Schwabe
Journal:  Pediatr Blood Cancer       Date:  2015-06-24       Impact factor: 3.167

2.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

3.  Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

Authors:  Dennis A Eichenauer; Annette Plütschow; Stefanie Kreissl; Martin Sökler; Johannes C Hellmuth; Julia Meissner; Stephan Mathas; Max S Topp; Karolin Behringer; Wolfram Klapper; Georg Kuhnert; Markus Dietlein; Carsten Kobe; Michael Fuchs; Volker Diehl; Andreas Engert; Peter Borchmann
Journal:  Lancet Oncol       Date:  2017-11-10       Impact factor: 41.316

4.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Authors:  Eric D Jacobsen; Jeff P Sharman; Yasuhiro Oki; Ranjana H Advani; Jane N Winter; Celeste M Bello; Gary Spitzer; Maria Corinna Palanca-Wessels; Dana A Kennedy; Pamela Levine; Jing Yang; Nancy L Bartlett
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

5.  Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.

Authors:  James Slack; Michael H Albert; Dmitry Balashov; Bernd H Belohradsky; Alice Bertaina; Jack Bleesing; Claire Booth; Jochen Buechner; Rebecca H Buckley; Marie Ouachée-Chardin; Elena Deripapa; Katarzyna Drabko; Mary Eapen; Tobias Feuchtinger; Andrea Finocchi; H Bobby Gaspar; Sujal Ghosh; Alfred Gillio; Luis I Gonzalez-Granado; Eyal Grunebaum; Tayfun Güngör; Carsten Heilmann; Merja Helminen; Kohei Higuchi; Kohsuke Imai; Krzysztof Kalwak; Nubuo Kanazawa; Gülsün Karasu; Zeynep Y Kucuk; Alexandra Laberko; Andrzej Lange; Nizar Mahlaoui; Roland Meisel; D Moshous; Hideki Muramatsu; Suhag Parikh; Srdjan Pasic; Irene Schmid; Catharina Schuetz; Ansgar Schulz; Kirk R Schultz; Peter J Shaw; Mary A Slatter; Karl-Walter Sykora; Shinobu Tamura; Mervi Taskinen; Angela Wawer; Beata Wolska-Kuśnierz; Morton J Cowan; Alain Fischer; Andrew R Gennery
Journal:  J Allergy Clin Immunol       Date:  2017-04-07       Impact factor: 10.793

6.  Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry.

Authors:  C R Pinkerton; I Hann; C L Weston; T Mapp; A Wotherspoon; R Hobson; D A Kelly; D Vergani; D Hadzic; L Rees; M Burke; J Alero Thomas
Journal:  Br J Haematol       Date:  2002-08       Impact factor: 6.998

7.  Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Keenan Fenton; Dirk Huebner; Juan M Pinelli; Dana A Kennedy; Andrei Shustov
Journal:  Blood       Date:  2017-10-03       Impact factor: 22.113

8.  Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

Authors:  Franco Locatelli; Christine Mauz-Koerholz; Kathleen Neville; Anna Llort; Auke Beishuizen; Stephen Daw; Marta Pillon; Nathalie Aladjidi; Thomas Klingebiel; Judith Landman-Parker; Aurora Medina-Sanson; Keith August; Jessica Sachs; Kristen Hoffman; Judith Kinley; Sam Song; Gregory Song; Stephen Zhang; Ajit Suri; Lia Gore
Journal:  Lancet Haematol       Date:  2018-10       Impact factor: 18.959

9.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Authors:  Steven Horwitz; Owen A O'Connor; Barbara Pro; Tim Illidge; Michelle Fanale; Ranjana Advani; Nancy L Bartlett; Jacob Haaber Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Andrei Shustov; Andreas Hüttmann; Kerry J Savage; Sam Yuen; Swaminathan Iyer; Pier Luigi Zinzani; Zhaowei Hua; Meredith Little; Shangbang Rao; Joseph Woolery; Thomas Manley; Lorenz Trümper
Journal:  Lancet       Date:  2018-12-04       Impact factor: 79.321

10.  Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma.

Authors:  Efren Rael; Kevin Rakszawski; Kristian Koller; Michael Bayerl; Manish Butte; Hong Zheng
Journal:  Biomark Res       Date:  2016-03-09
View more
  1 in total

Review 1.  The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers.

Authors:  Frederic Baleydier; Fanette Bernard; Marc Ansari
Journal:  Biomolecules       Date:  2020-07-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.